Extrapulmonary manifestations of COVID-19
By Aakriti Gupta, Mahesh V. Madhavan, K. Sehgal, N. Nair, S. Mahajan, Tejasav S. Sehrawat, B. Bikdeli, N. Ahluwalia, John Ausiello, E. Wan and 19 more. Nature Medicine, 2020
2,748 citations recorded by the source corpus.
Although COVID-19 is most well known for causing substantial respiratory pathology, it can also result in several extrapulmonary manifestations. These conditions include thrombotic complications, myocardial dysfunction and arrhythmia, acute coronary syndromes, acute kidney injury, gastrointestinal symptoms, hepatocellular injury, hyperglycemia and ketosis, neurologic illnesses, ocular symptoms, and dermatologic complications. Given that ACE2, the entry receptor for the causative coronavirus SARS-CoV-2, is expressed in multiple extrapulmonary tissues, direct viral tissue damage is a plausible mechanism of injury. In addition, endothelial damage and thromboinflammation, dysregulation of immune responses, and maladaptation of ACE2-related pathways might all contribute to these extrapulmonary manifestations of COVID-19. Here we review the extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved. Recent clinical observations have prompted clinicians to think of COVID-19 as being more than a respiratory disease.
Subfields: Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/44d33c3c1d2846ad430403c39b9384d063ed958b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- COVID-19 and the human innate immune system (2021, background): “Disease courses range from mainly asymptomatic and mild courses to more severe and critical courses in 10%–20% of symptomatic patients who are at considerable risk of fatality with many different organ systems involved in differing combinations and with variable symptoms (Gupta et al., 2020) (Box 1)”
- Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms (2021, background): “, 2020a) and related thromboinflammation, dysregulation of the renin–angiotensin– aldosterone system, and endothelial cell damage (Grobler et al., 2020; Gupta et al., 2020).”